UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________________________________________

FORM 6-K

________________________________________________________

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2023

Commission File Number: 001-39152

________________________________________________________

FSD PHARMA INC.

(Registrant)

________________________________________________________

199 Bay St., Suite 4000

Toronto, Ontario M5L 1A9 Canada

 (Address of Principal Executive Offices) 

________________________________________________________

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	FSD PHARMA INC.
	(Registrant)
Date November 6, 2023	By	/s/ Nathan Coyle
		Nathan Coyle
		Chief Financial Officer

2

EXHIBIT INDEX

Exhibit	Description of Exhibit
99.1	News Release dated September 18, 2023 – FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis. The Report Shows Compound to be Safe and Well Tolerated
99.2	News Release dated October 4, 2023 – FSD Pharma Wins $2.8 Million Dollar Award Plus Accruing Interest from Dr. Raza Bokhari; Set Aside Motion Brought by Bokhari, Now CEO of Medicus Pharma, Dismissed by the Ontario Superior Court of Justice
99.3	News Release dated October 5, 2023 – FSD Pharma and Celly NU Enter into Arrangement Agreement

3